Las drogas son malas, eso lo sabemos todos, ¿pero eso aplica siempre? Descubre cómo un alucinógeno milenario puede ser un aliado inesperado en la lucha contra las enfermedades psiquiátricas, claro, con un café a mano. Moderadores: Hans Liebisch, Lina Martinez y Juan Francisco Guevara Artículos complementarios: Daniel J, Haberman M. Clinical potential of psilocybin as a treatment for mental health conditions. Ment Health Clin. 2018;7(1):24-28. Published 2018 Mar 23. doi:10.9740/mhc.2017.01.024 Geiger, H. A., Wurst, M. G., & Daniels, R. N. (2018). DARK Classics in Chemical Neuroscience: Psilocybin. ACS Chemical Neuroscience. doi:10.1021/acschemneuro.8b00186 Nichols, David E. “Psychedelics.” Pharmacological reviews vol. 68,2 (2016): 264-355. doi:10.1124/pr.115.011478 Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology, 29(3), 289–299. doi:10.1177/0269881114565144 Sachdeva, A. (2015). Alcohol Withdrawal Syndrome: Benzodiazepines and Beyond. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. doi:10.7860/jcdr/2015/13407.6538 Lim, T. H., Wasywich, C. A., & Ruygrok, P. N. (2012). A fatal case of “magic mushroom” ingestion in a heart transplant recipient. Internal Medicine Journal, 42(11), 1268–1269. doi:10.1111/j.1445-5994.2012.02955.x Madsen, M. K., Fisher, P. M., Stenbæk, D. S., Kristiansen, S., Burmester, D., Lehel, S., … Knudsen, G. M. (2020). A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. European Neuropsychopharmacology. doi:10.1016/j.euroneuro.2020.02.001 Goldberg, S. B., Pace, B. T., Nicholas, C. R., Raison, C. L., & Hutson, P. R. (2020). The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry Research, 112749. doi:10.1016/j.psychres.2020.112749
